Eli Lilly Sues Telehealth Start-Ups Over GLP-1 Knockoffs
Pharma giant Eli Lilly filed suits against four telehealth companies for allegedly selling compounded, off-brand versions of its weight-loss drugs Mounjaro and Zepbound, claiming safety risks and trademark infringement. Demand for GLP-1 medications remains sky-high after shortages, fueling a gray market.
|
Want to dive deeper?
We've prepared an in-depth analysis of this story with additional context and background.
Featuring Our Experts' Perspectives in an easy-to-read format.
Read Deep DiveRelated Roadmaps
Explore step-by-step guides related to this story, designed to help you apply this knowledge in your life.
Loading roadmaps...
Please wait while we find relevant roadmaps for you.
Your Opinion
Would you try cheaper compounded meds if brand names are back-ordered?
Log in to have your vote counted in your profile.
React to this story
Click to react! Your feedback helps us understand what matters to you.
Comments (0)
Log in or create an account to join the conversation.
Share this story
Help your network stay informed by sharing this story.
Related News
World Immunization Week Champions Vaccine Success Stories
Amid ongoing public health challenges, global institutions are celebrating World Immunization Week, spotlighting the transformative power of...
Utah Pulls Plug on Free Therapy for Farmers Despite Suicide Crisis
Amid soaring mental health struggles in rural America, Utah abruptly ended its free counseling vouchers for farmers, leaving a vulnerable...
Midlife Exercise Linked to Lower Alzheimer’s Risk in Later Years
New research reveals that boosting physical activity between ages 45 and 65 can significantly reduce Alzheimer’s disease risk in older adulthood....
Be the first to comment on this story!